Hey Reader,
Ready for a pop quiz?
Thanks to a little-known investment secret…
One man was able to build a single $1,000 investment into a $70,000 income stream – after 60 years – without touching a single stock!
Click Here to Reveal the Answer!
Listen…
It doesn’t matter whether you get it right or wrong…
What matters is that you go here now for the answer.
Because I’ve just uncovered a similar opportunity that could help YOU collect double-digit income from this very sector for yourself.
As of right now, it’s still virtually unknown.
But I don’t expect it to stay that way for long.
So if you want a first mover advantage, you need to check it out ASAP.
Good investing,
Marc Lichtenfeld
Chief Income Strategist, The Oxford Club
P.S. I’d guess only 1 in 100 readers will get this right. And I’m curious if that’ll be you. Find out here.
RYTM’s $10B Offer Undersells the Pipeline
The headline number is striking: AstraZeneca has made an offer of about $10 billion to acquire Rhythm Pharmaceuticals. The non-binding proposal values the company at as much as $134 a share, including milestone payments. RYTM shareholders collected a 28% single-day gain on the news. The more interesting question is whether that gain is a ceiling or a floor.
The Bull Case
Rhythm’s approved therapy Imcivree treats rare obesity caused by specific genetic defects, and in March 2026 the FDA expanded its use to acquired hypothalamic obesity, a form of obesity caused by damage to the hypothalamus. That expansion is already moving revenue at a meaningful clip. Third-quarter 2026 net product revenue from global IMCIVREE sales reached $92.1 million, an increase of 29% from the prior quarter, with more than 700 patient start forms filed as of September 30. Japan is now a live market, and Europe has followed the U.S. with its own authorization.
Then there is what AstraZeneca’s bid arguably ignores. Jefferies analyst Dennis Ding argues the offer reflects minimal valuation for Rhythm’s Prader-Willi syndrome program, including bivamelagon, an MC4R-specific agonist entering Phase 3 development. William Blair projected Imcivree alone could reach $3.6 billion in annual sales by 2032, not including any approval in Prader-Willi syndrome. If bivamelagon delivers in both hypothalamic obesity and Prader-Willi, the platform value sits well above $134 a share.
At least three analyst teams suggest a bidding war could be brewing and that Rhythm is unlikely to settle for AstraZeneca’s current pitch. William Blair’s Alethia Young noted that any large-cap biopharma with a metabolic business could be interested in Rhythm. That is a wide competitive field.
The Bear Case
Rhythm is not a bargain business at current levels. As of September 30, 2026, the company carried an accumulated deficit of about $1.5 billion and posted a net loss of $41.4 million in the quarter. The pivot to profitability depends entirely on Imcivree scaling faster than operating costs, and on bivamelagon clearing Phase 3 trials without a stumble.
The competitive pressure on Rhythm’s platform extends beyond AstraZeneca’s bid. Viking Therapeutics has demonstrated that a rival obesity mechanism can match GLP-1 efficacy at lower dosing frequency, raising the bar any rare-obesity platform must clear to justify premium valuations.
CEO David Meeker acknowledged on the Q3 call that Prader-Willi is an incredibly challenging disease, noting that almost all prior therapies have failed. That is not a reason to dismiss the program, but it is a reason to discount the probability-weighted value that bulls are ascribing to it. AstraZeneca’s existing bid may reflect exactly that caution rather than carelessness.
AstraZeneca itself has faced clinical trial setbacks recently, and reports of a potential mega-merger with Bristol Myers Squibb had already weighed on its shares. Alongside its Q3 results, AstraZeneca disclosed a restructuring program that it said is expected to deliver $1.5 billion in annualized pre-tax run-rate benefits. A buyer under self-imposed cost discipline has less room to get competitive in a bidding war.
Where the Evidence Leads
The bull case rests on a pipeline that AstraZeneca’s current offer genuinely undervalues. The bear case rests on clinical risk and a buyer whose own balance sheet is tightening. Both are real. The more credible near-term question is not whether $134 is fair, but whether a competing bid forces a renegotiation before Rhythm’s board responds. If bivamelagon’s Phase 3 readouts arrive while M&A negotiations are open, Rhythm holds significant leverage. If trials slip, the offer on the table suddenly looks generous.
The balance of evidence favors shareholders holding out. The pipeline is commercially validated, the revenue trajectory is clean, and the analyst community is nearly unanimous that the current price undersells what comes next. Watch for a formal counter or a new bidder before year-end.
